New York, Feb 10, 2026, 07:03 EST — Premarket
- ImmunityBio held steady in premarket action, following Monday’s 14.6% surge.
- Shares finished the session at $6.93 on Feb. 9, having touched $7.03 earlier in the day.
- Next up for investors: the company’s quarterly results, anticipated in early March.
ImmunityBio, Inc. held steady at $6.93 in Tuesday’s premarket, following a big 14.6% jump to that same price on Monday.
That shift keeps the cancer immunotherapy company in focus as traders debate if its flagship product can keep up the pace—and if a pipeline of clinical and regulatory news will finally deliver more consistent revenue. Anktiva, the company’s approved treatment, is paired with BCG, the weakened bacterium commonly used for bladder cancer, targeting patients with non-muscle invasive bladder cancer, or NMIBC.
This year, the stock’s trajectory has mirrored its evolution from “clinical-stage” to “commercial-stage”—investors now zero in on sales numbers instead of waiting around for results from trials further down the line. Back in mid-January, the company posted preliminary net product revenue for 2025 at around $113 million, marking a year-over-year jump of about 700%. Business Wire
Lately, ImmunityBio has kicked off a Phase 2 trial looking at a combination of ANKTIVA and an off-the-shelf CAR-NK cell therapy—notably without chemotherapy or lymphodepletion—for patients with indolent B-cell non-Hodgkin lymphoma.
Attention has shifted again to the regulators. ImmunityBio, back in January, reported it was in advanced talks with the U.S. Food and Drug Administration regarding a possible resubmission route for ANKTIVA aimed at BCG-unresponsive papillary bladder cancer.
ImmunityBio’s Anktiva faces off with Merck’s Keytruda and Ferring’s Adstiladrin in the NMIBC space, all contending for a spot in doctors’ treatment plans for certain BCG-unresponsive patients looking to sidestep bladder removal.
ImmunityBio shares swung from $5.82 to $7.03 on Monday, ending the day at $6.93. Trading volume hit roughly 23.9 million, based on Yahoo Finance figures.
Equity holders face a significant risk around financing and dilution. Back in January, an 8-K detailed changes to a $505 million convertible note held by an affiliate of executive chairman Patrick Soon-Shiong, opening the door for some of the principal to be swapped for common stock ahead of its maturity.
Wall Street analysts are zeroing in on revenue. In January, Piper Sandler’s Joseph Catanzaro pointed out U.S. ANKTIVA net revenue shot up roughly 700%, reaching $113 million in 2025. The firm bumped its price target for the stock up to $7 from $5, sticking with its Overweight call.
Next up: earnings. Zacks says ImmunityBio is slated to deliver its quarterly numbers March 2.
